Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure

European Heart Journal

Volumn 24, Issue 18, 2003, Pages 1657-1662

  Gould, Paul A ^a   Esler, Murray D ^a   Kaye, David M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atrial fibrillation; Heart failure; Sympathetic activity

Indexed keywords

NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART OUTPUT; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; SYMPATHETIC TONE;

ATRIAL FIBRILLATION; BLOOD PRESSURE; CHRONIC DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; SYMPATHETIC NERVOUS SYSTEM;

EID: 0141538225     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00393-2     Document Type: Article

References (50)

1. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial. Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001;104(17):2118-50.
2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22(17):1527-60.
3. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999;5(4):357-382.
4. Krum H. Guidelines for management of patients with chronic heart failure in Australia. Med J Aust 2001;174(9):459-66.
5. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98(10):946-52.
6. Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32(3):695-703.
7. Kannel WB, Cupples A. Epidemiology and risk profile of cardiac failure. Cardiovasc Drugs Ther 1988;2(Suppl 1):387-95.
8. Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317(11):669-74.
9. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840-4.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429-35.
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.
12. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334(21): 1349-55.
13. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353(9169):2001-7.
14. Hasking GJ, Esler MD, Jennings GL et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73(4):615-21.
15. Kaye DM, Lambert GW, Lefkovits J et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23(3):570-8.
16. Leimbach WN Jr, Wallin BG, Victor RG et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73(5):913-9.
17. Kaye DM, Lefkovits J, Jennings GL et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26(5):1257-63.
18. Meredith IT, Broughton A, Jennings GL et al. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325(9):618-24.
19. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311(13):819-23.
20. Esler M, Jennings G, Lambert G et al. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990;70(4):963-85.
21. Esler M, Jackman G, Bobik A et al. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 1979;25(17): 1461-70.
22. Goldstein DS, Feuerstein G, Izzo JL Jr et al. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 1981;28(5):467-75.
23. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341(8):577-85.
24. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20(1):248-54.
25. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984;69(4):790-800.
26. Mann DL, Kent RL, Parsons B et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85(2):790-804.
27. Kannel WB, Abbott RD, Savage DD et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306(17):1018-22.
28. Chugh SS, Blackshear JL, Shen WK et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37(2):371-8.
29. Esler MD, Thompson JM, Kaye DM et al. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Circulation 1995;91(2):351-8.
30. Esler M, Kaye D, Lambert G et al. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80(11A):7L-14L.
31. Kaye DM, Jennings GL, Dart AM et al. Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic tone in congestive heart failure. J Am Coll Cardiol 1998;31(3):583-7.
32. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J 1994;15(Suppl A):9-16.
33. Schauerte P, Scherlag BJ, Patterson E et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol 2001;12(5):592-9.
34. Hohnloser SH, van de Loo A, Klingenheben T. [Atrial fibrillation and the autonomic nervous system]. Z Kardiol 1994;83(Suppl 5):21-7.
35. Chen YJ, Tai CT, Chiou CW et al. Inducibitity of atrial fibrillation during atrioventricular pacing with varying intervals: role of atrial electrophysiology and the autonomic nervous system. J Cardiovasc Electrophysiol 1999;10(12):1578-85.
36. Jayachandran JV, Sih HJ, Winkle W et al. Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation 2000;101(10): 1185-91.
37. Chang CM, Wu TJ, Zhou S et al. Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. Circulation 2001;103(1):22-5.
38. Wasmund SL, Li JM, Page RL et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 2003;107(15):2011-5.
39. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984;69(3):451-60.
40. Thames MD, Waickman LA, Abboud FM. Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin. Am J Physiol 1980;239(5):H628-35.
41. Thames MD. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979;44(1):8-15.
42. Goldsmith SR, Simon AB, Miller E. Effect of digitalis on norepinephrine kinetics in congestive heart failure. J Am Coll Cardiol 1992;20(4):858-63.
43. Kaye DM, Johnston L, Vaddadi G et al. Mechanisms of carvedilol action in human congestive heart failure. Hypertension 2001;37(5): 1216-21.
44. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333(2):77-82.
45. Doval HC, Nul DR, Grancelli HO et al. Randomised trial of Low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de La Sobrevida en La Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344(8921):493-8.
46. Kaye DM, Dart AM, Jennings GL et al. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol 1999;33(6):1553-9.
47. Brignole M, Menozzi C, Gianfranchi L et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998;98(10):953-60.
48. Daubert Jean-Claude LC, Cazeau S, Kappenberger L et al. Clinical Effects of Biventricular Pacing in Patients with Severe Heart Failure and Chronic Atrial Fibrillation: Results from the Multisite Stimulation in Cardiomyopathy-MUSTIC Study-Group II. Circulation 2000;102(18(Suppl II 'abstr')):693.
49. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344(12):873-80.
50. Joglar JA, Acusta AP, Shusterman NH et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001;142(3):498-501.